Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort studyServet Altay1, Hüseyin Altuğ Çakmak2, Tuğba Kemaloğlu Öz3, Fatma Özpamuk Karadeniz3, Ayça Türer5, Hatice Betül Erer3, Gülen Feyzan Kılıç4, İbrahim Keleş6, Günay Can7, Mehmet Eren3
1Department of Cardiology, Faculty of Medicine, Trakya University; Edirne-Turkey
2Department of Cardiology, Mustafa Kemalpaşa State Hospital; Bursa-Turkey
3Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital; İstanbul-Turkey
4Department of Biochemistry, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital; İstanbul-Turkey
5Department of Cardiology, Faculty of Medicine, Yeditepe University; İstanbul-Turkey
6Department of Cardiology, Cerrahpaşa Faculty of Medicine, İstanbul University, İstanbul; Ankara-Turkey
7Department of Public Health, Cerrahpaşa Faculty of Medicine, İstanbul University, İstanbul; Ankara-Turkey
Objective: A predictive role of serum Pentraxin 3 (PTX3) for short-term adverse cardiovascular events including mortality in acute myocardial infarction (AMI) was reported in recent studies. The aim of the study was to investigate long-term prognostic significance of serum PTX3 in an AMI with 5-year follow-up period in this study.Keywords: pentraxin-3, acute myocardial infarction, long-term prognosis, mortality, cardiovascular event
Methods: In this prospective study, 140 patients, who were admitted to the emergency department between January 2011 and December 2011 with acute chest pain and/or dyspnea and diagnosed with AMI and 60 healthy controls were included. PTX3 levels were measured at admission by using an ELISA method. The study group was divided into tertiles on the basis of admission PTX3 values: the high-PTX3 group (≥4.27 ng/mL), the middle-PTX3 groups (4.271.63 ng/mL), and the low-PTX3 group (≤1.63 ng/mL).
Results: PTX3 level was significantly more greatly increased in the AMI group than in the controls (2.27±0.81 vs. 0.86±0.50 ng/mL, p<0.001). PTX3 level was found to be significantly positively correlated with TIMI score (r=0.368, p=0.037), high sensitive C-reactive protein (hsCRP) (r=0.452, p=0.024), pro-BNP (r=0.386, p=0.029), troponin I (r=0.417, p=<0.001), and GRACE score (r=0.355, p=0.045), and negatively correlated with HDL cholesterol (r=0.203, p=0.016) and LVEF (r=0.345, p=0.028). In multivariate analysis, PTX3 (OR=1.12, 95% CI 1.041.20; p=0.001) was a significant independent predictor of long-term cardiovascular mortality, after adjusting for other risk factors.
Conclusion: PTX3 is a novel biomarker that may help to identify high risk individuals with AMI, who are potentially at risk of early major adverse cardiovascular events including mortality in the long-term period. (Anatol J Cardiol 2017; 17: 202-9)
Servet Altay, Hüseyin Altuğ Çakmak, Tuğba Kemaloğlu Öz, Fatma Özpamuk Karadeniz, Ayça Türer, Hatice Betül Erer, Gülen Feyzan Kılıç, İbrahim Keleş, Günay Can, Mehmet Eren. Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study. Anatol J Cardiol. 2017; 17(3): 202-209
Corresponding Author: Servet Altay, Türkiye